Results 71 to 80 of about 136,983,672 (229)

Orexin/hypocretin role in reward: implications for opioid and other addictions

open access: yes, 2017
Addiction is a devastating disorder that affects 15.3 million people worldwide. While prevalent, few effective treatments exist. Orexin receptors have been proposed as a potential target for anti-craving medications.
邱麗珠   +1 more
core   +1 more source

Novel targets in headache: A narrative review

open access: yesHeadache: The Journal of Head and Face Pain, EarlyView.
Abstract Objectives/Background This narrative review summarizes novel applications for the use of calcitonin gene‐related peptide (CGRP)‐targeted therapies that go beyond migraine, the latest updates with respect to targeting pituitary adenylate cyclase‐activating peptide (PACAP) as therapeutic in migraine, as well as exploring other more recently ...
Adriana Della Pietra   +5 more
wiley   +1 more source

Roles of orexin in modulating arousal, feeding and motivation

open access: yesFrontiers in Behavioral Neuroscience, 2013
Orexin deficiency results in narcolepsy in humans, dogs, and rodents, suggesting that the orexin system is particularly important for maintenance of wakefulness.
Natsuko eTsujino, Takeshi eSakurai
doaj   +1 more source

Use of Dual Orexin Receptor Antagonists for Insomnia and the Risk of Falls and Fractures: A Systematic Review and Meta‐Analysis

open access: yesJournal of the American Geriatrics Society, EarlyView.
ABSTRACT Background Falls are the leading cause of injury in older adults. Sedative‐hypnotic use is a known risk factor, but their use for insomnia continues to be common. Dual orexin receptor antagonists (DORAs) are a new, potentially safer class of medications for insomnia.
Arianna Paolone   +5 more
wiley   +1 more source

Hip Fracture Risk of Lemborexant and Suvorexant in Comparison With Z‐Drugs: A Target Trial Emulation

open access: yesJournal of the American Geriatrics Society, EarlyView.
ABSTRACT Background Lemborexant and suvorexant are widely used dual orexin receptor antagonists (DORAs) for the pharmacological treatment of insomnia. Although they are generally considered safer than benzodiazepine receptor agonists (Z‐drugs) regarding adverse events including hip fractures, evidence from direct comparisons remains limited. This study
Yuichiro Matsuo   +5 more
wiley   +1 more source

Chronic insomnia, REM sleep instability and emotional dysregulation: A pathway to anxiety and depression?

open access: yesJournal of Sleep Research, Volume 34, Issue 2, April 2025.
Summary The world‐wide prevalence of insomnia disorder reaches up to 10% of the adult population. Women are more often afflicted than men, and insomnia disorder is a risk factor for somatic and mental illness, especially depression and anxiety disorders.
Dieter Riemann   +13 more
wiley   +1 more source

Orexin and Alzheimer’s Disease

open access: yes, 2016
Alzheimer's disease (AD) is the most frequent age-related dementia. It prevalently causes cognitive decline, although it is frequently associated with secondary behavioral disturbances. AD neurodegeneration characteristically produces a remarkable destruction of the sleep-wake cycle, with diurnal napping, nighttime arousals, sleep fragmentation, and ...
openaire   +3 more sources

Narcolepsy and rapid eye movement sleep

open access: yesJournal of Sleep Research, Volume 34, Issue 2, April 2025.
Summary Since the first description of narcolepsy at the end of the 19th Century, great progress has been made. The disease is nowadays distinguished as narcolepsy type 1 and type 2. In the 1960s, the discovery of rapid eye movement sleep at sleep onset led to improved understanding of core sleep‐related disease symptoms of the disease (excessive ...
Francesco Biscarini   +4 more
wiley   +1 more source

Ageing‐related modification of sleep and breathing in orexin‐knockout narcoleptic mice

open access: yesJournal of Sleep Research, Volume 34, Issue 2, April 2025.
Summary Narcolepsy type‐1 (NT1) is a lifelong sleep disease, characterised by impairment of the orexinergic system, with a typical onset during adolescence and young adulthood. Since the wake–sleep cycle physiologically changes with ageing, this study aims to compare sleep patterns between orexin‐knockout (KO) and wild type (WT) control mice at ...
Stefano Bastianini   +7 more
wiley   +1 more source

Parasomnias and sleep‐related movement disorders induced by drugs in the adult population: a review about iatrogenic medication effects

open access: yesJournal of Sleep Research, Volume 34, Issue 2, April 2025.
Summary Parasomnias and sleep‐related movement disorders (SRMD) are major causes of sleep disorders and may be drug induced. The objective of this study was to conduct a systematic review of the literature to examine the association between drug use and the occurrence of parasomnias and SRMD.
Sylvain Dumont   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy